4.
The relationship of Ki-67 expression with the molecular subtypes, immunohistochemical characteristics of breast cancer and patient outcome, n (%).
| Ki-67 | P | ||
| <15% | >15% | ||
| ER | 0.027 * | ||
| Negative | 28 (39) | 22 (61) | |
| Positive | 43 (61) | 14 (39) | |
| PR | 0.014 * | ||
| Negative | 26 (37) | 22 (61) | |
| Positive | 45 (63) | 14 (39) | |
| HER2 | 0.4 | ||
| Negative | 58 (82) | 28 (78) | |
| Positive | 13 (18) | 8 (22) | |
| Molecular subtypes | 0.00 * | ||
| Luminal A | 44 (100) | 0 (0) | |
| Luminal B | 7 (30) | 16 (70) | |
| HER2 | 10 (67) | 5 (33) | |
| Triple-negative | 10 (40) | 15 (60) | |
| Alive or dead | 0.01 * | ||
| Alive | 61 (86) | 23 (64) | |
| Dead | 10 (14) | 13 (36) | |
| Recurrence & metastasis | 0.00 * | ||
| Negative | 59 (83) | 16 (44) | |
| Positive | 12 (17) | 20 (56) | |